Japanese biopharmaceutical firm Anges Inc said on Tuesday it and partner Osaka University had completed development of a prophylactic DNA vaccine against the new coronavirus and that it would begin testing it in animals soon.
Published : 24 Mar 2020, 05:21 PM
Shares of Anges were untraded with a glut of buy orders in early morning.
There are now more than 350,000 cases of coronavirus infections globally and over 15,000 deaths resulting from the disease it causes, called COVID-19.